Trial Profile
A Phase II study of TZ101-fucosylated bone marrow stem cells from haplo-identical donors to evaluate the safety and efficacy in patients undergoing bone marrow transplantation for treatment of hematologic malignancies: Haplo-identical transplant study
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2016
Price :
$35
*
At a glance
- Drugs TZ 101 (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- 09 Nov 2016 New trial record
- 24 Oct 2016 According to a Targazyme media release, U.S. FDA has granted IND Clearance to begin enrolling patients in this trial.